Caring Ambassadors Program

Hepatitis C Newsletter

November - December 2010



Clinical Trials, Cohort Studies, Pilot Studies


Safety and pharmacokinetics of IDX184, a liver-targeted nucleotide polymerase inhibitor of the hepatitis c virus, in healthy subjects. Zhou XJ, Pietropaolo K, Chen J, Khan S, Sullivan-Bólyai J, Mayers D. Antimicrob Agents Chemother. 2010 Nov 8. [Epub ahead of print]


Changes in insulin sensitivity and body weight during and after peginterferon and ribavirin therapy for hepatitis C. Conjeevaram HS, Wahed AS, Afdhal N, et al. Gastroenterology. 2010 Nov 8. [Epub ahead of print]


Long-term outcome after antiviral therapy of patients with hepatitis C virus infection and decompensated cirrhosis. Iacobellis A, Perri F, Valvano MR, Caruso N, Niro GA, Andriulli A. Clin Gastroenterol Hepatol. 2010 Nov 16. [Epub ahead of print]


Hepatitis C treatment among racial and ethnic groups in the IDEAL trial. Muir AJ, Hu KQ, Gordon SC, et al. J Viral Hepat. 2010 Nov 25. doi: 10.1111/j.1365-2893.2010.01402.x. [Epub ahead of print]


Randomized controlled trial of pegylated interferon-alfa 2a and ribavirin in treatment-naive chronic hepatitis C genotype 6. Lam KD, Trinh HN, Do ST, et al. Hepatology. 2010 Nov;52(5):1573-80.


Frequent multiple hepatitis C virus infections among injection drug users in a prison setting. Pham ST, Bull RA, Bennett JM, et al. Hepatology. 2010 Nov;52(5):1564-72.


Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project. Lindenburg CE, Lambers FA, Urbanus AT, et al. Eur J Gastroenterol Hepatol. 2010 Oct 29. [Epub ahead of print]


Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response. Buti M, Lurie Y, Zakharova NG, et al. Hepatology. 2010 Oct;52(4):1201-7.


Systemic vasculitis in patients with hepatitis C virus infection with and without detectable mixed cryoglobulinemia. Terrier B, Sčne D, Dechartres A, et al. J Rheumatol. 2010 Oct 15. [Epub ahead of print]


Sporadic reappearance of minute amounts of HCV RNA after successful therapy stimu-lates cellular immune responses. Veerapu NS, Raghuraman S, Liang TJ, Heller T, Rehermann B. Gastroenterology. 2010 Oct 29. [Epub ahead of print]


Cervicovaginal shedding of hepatitis C viral RNA is associated with the presence of menstrual or other blood in cervicovaginal fluids. Wang CC, Cook L, Tapia KA, et al. J Clin Virol. 2010 Oct 14. [Epub ahead of print]


Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): A randomised, double-blind, placebo-controlled, dose-escalation trial. Gane EJ, Roberts SK, Stedman CA, et al. Lancet. 2010 Oct 30;376(9751):1467-75. Epub 2010 Oct 14.


The combination of ribavirin and peginterferon is superior to peginterferon and placebo for children and adolescents chronic hepatitis C. Schwarz KB, Gonzalez-Peralta RP, Murray KF, et al. . Gastroenterology. 2010 Oct 28. [Epub ahead of print]


Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or 2b to patients with chronic hepatitis C. Marcellin P, Forns X, Goeser T, et al. Gastro-enterology. 2010 Oct 26. [Epub ahead of print]


Prophylactic treatment with escitalopram of pegylated interferon alfa-2a-induced depression in hepatitis c: a 12-week, randomized, double-blind, placebo-controlled trial.

Diez-Quevedo C, Masnou H, Planas R, et al. J Clin Psychiatry. 2010 Oct 5. [Epub ahead of print]


A multidisciplinary therapeutic approach for reducing the risk of psychiatric side effects in patients with chronic hepatitis C treated with pegylated interferon α and ribavirin.

Neri S, Bertino G, Petralia A, et al. J Clin Gastroenterol. 2010 Oct;44(9):e210-7.


Basic and Applied Science, Pre-Clinical Studies


Survival of hepatitis C virus in syringes: implication for transmission among injection drug users. Paintsil E, He H, Peters C, Lindenbach BD, Heimer R. J Infect Dis. 2010 Oct 1;202(7):984-90.



Hepatitis C virus-specific CD8+ T cell frequencies are associated with the responses of pegylated interferon-α and ribavirin combination therapy in patients with chronic hepatitis C virus infection. Tatsumi T, Takehara T, Miyagi T, et al. Hepatol Res. 2010 Oct 7. doi: 10.1111/j.1872-034X.2010.00734.x. [Epub ahead of print]


Early viral and peripheral blood mononuclear cell responses to pegylated interferon and ribavirin treatment: the first 24h. Devitt E, Lawless MW, Sadlier D, A Browne J, Walsh C, Crowe J. Eur J Gastroenterol Hepatol. 2010 Oct;22(10):1211-20.


Increased natural killer cell cytotoxicity and NKp30 expression protects against hepatitis C virus infection in high-risk individuals and inhibits replication in vitro. Golden-Mason L, Cox AL, Randall JA, Cheng L, Rosen HR. Hepatology. 2010 Nov;52(5):1581-9.


DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin a induced cis-trans isomerisation in domain II of NS5A. Coelmont L, Hanoulle X, Chatterji U, et al. PLoS One. 2010 Oct 27;5(10):e13687.


CX3CL1-CX3CR1 interaction prevents carbon tetrachloride-induced liver inflammation and fibrosis in mice. Aoyama T, Inokuchi S, Brenner DA, Seki E. Hepatology. 2010 Oct;52(4):1390-400.


Conformational anti-cytochrome P4502E1 (CYP2E1) auto-antibodies contribute to necro-inflammatory injury in chronic hepatitis C. Sutti S, Vidali M, Mombello C, Sartori M, Albano E. J Viral Hepat. 2010 Oct;17(10):685-90. doi: 10.1111/j.1365-2893.2010.01359.x.


A new natural α-helical peptide from the venom of the scorpion Heterometrus petersii kills HCV. Yan R, Zhao Z, He Y, et al. Peptides. 2010 Oct 13. [Epub ahead of print]


Dynamic coinfection with multiple viral subtypes in acute hepatitis C. Smith JA, Aberle JH, Fleming VM, et al.


HIV/HCV Coinfection


Modeling the probability of sustained virological response to Therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV. Medrano J, Neukam K, Rallón N, et al. Clin Infect Dis. 2010 Nov 15;51(10):1209-16.





Polymorphism in tumor necrosis factor-related apoptosis-inducing ligand receptor 1 is associated with poor viral response to interferon-based hepatitis C virus therapy in HIV/hepatitis C virus-coinfected individuals. Rizza SA, Cummins NW, Rider DN, Saeed S, Klein MB, Badley AD. AIDS. 2010 Nov 13;24(17):2639-44.


Transient elastography: a non-invasive tool for assessing liver fibrosis in HIV/HCV patients. Li Vecchi V, Soresi M, Colomba C, et al. World J Gastroenterol. 2010 Nov 7;16(41): 5225-32.


The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): Early findings, 2006-2010. Loko MA, Salmon D, Carrieri P, et al. BMC Infect Dis. 2010 Oct 22;10(1):303. [Epub ahead of print]


Immunological status does not influence hepatitis C virus or liver fibrosis in HIV-Hepatitis C virus-coinfected patients. Collazos J, Cartón JA, Asensi V. AIDS Res Hum Retroviruses. 2010 Oct 26. [Epub ahead of print]


Women experience higher rates of adverse events during hepatitis C virus therapy in HIV infection: a meta-analysis. Bhattacharya D, Umbleja T, Carrat F, et al. J Acquir Immune Defic Syndr. 2010 Oct 1;55(2):170-5.


Evaluation of the possible influence of hepatitis C virus and liver fibrosis on HIV type 1 immunological and virological outcomes. Collazos J, Cartón J, Asensi V. HIV Med. 2010 Oct 14. doi: 10.1111/j.1468-1293.2010.00886.x. [Epub ahead of print]


Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon-ribavirin therapy in patients with chronic hepatitis C virus infection. Morello J, Cuenca L, Soriano V, et al. J Infect Dis. 2010 Oct 15;202(8):1185-91.


Prevalence and factors associated with significant liver fibrosis assessed by transient elastometry in HIV/hepatitis C virus-coinfected patients. Pineda JA, González J, Ortega E, et al. J Viral Hepat. 2010 Oct;17(10):714-9. doi: 10.1111/j.1365-2893.2009.01229.x.


Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Pineda JA, Caruz A, Rivero A, et al. Clin Infect Dis. 2010 Oct 1;51(7):788-95.



Sustained Long-Term Antiviral Maintenance Therapy in HCV/HIV-Coinfected Patients (SLAM-C). Sherman KE, Andersen JW, Butt AA, et al. J Acquir Immune Defic Syndr. 2010 Oct 1. [Epub ahead of print]


An artificial neural network improves the non-invasive diagnosis of significant fibrosis in HIV/HCV coinfected patients. Resino S, Seoane JA, Bellón JM, et al. J Infect. 2010 Nov 10. [Epub ahead of print]


Treatment of acute hepatitis C in human immunodeficiency virus-infected patients: The HEPAIG study. Piroth L, Larsen C, Binquet C, et al. Hepatology. 2010 Dec;52(6):1915-21. doi: 10.1002/hep.23959. Epub 2010 Nov 9.


Complementary and Alternative Medicine


S-adenosyl-methionine and betaine improve early virological response in chronic hepatitis C patients with previous nonresponse. Filipowicz M, Bernsmeier C, Terracciano L, Duong FH, Heim MH. PLoS One. 2010 Nov 8;5(11):e15492.


Silymarin use and liver disease progression in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis trial. Freedman ND, Curto TM, Morishima C, et al. Aliment Pharmacol Ther. 2010 Nov 2. doi: 10.1111/j.1365-2036.2010.04503.x. [Epub ahead of print]


Epidemiology, Diagnostics, and Miscellaneous Works


Humanistic and economic impacts of hepatitis C infection in the United States. Dibona-ventura MD, Wagner JS, Yuan Y, L'italien G, Langley P, Ray Kim W. J Med Econ. 2010 Nov 22. [Epub ahead of print]


Formal patient education improves patient knowledge of hepatitis c in vulnerable popu-lations. Surjadi M, Torruellas C, Ayala C, Yee HF Jr, Khalili M. Dig Dis Sci. 2010 Oct 24. [Epub ahead of print]


Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1. Petta S, Amato M, Cabibi D, et al. Hepatology. 2010 Nov;52(5):1543-52.


Hepatic microRNA expression is associated with the response to interferon treatment of chronic hepatitis C. Murakami Y, Tanaka M, Toyoda H, et al. BMC Med Genomics. 2010 Oct 22;3:48.


Importance of Patient, Provider, and Facility Predictors of Hepatitis C Virus Treatment in Veterans: A National Study. Kramer JR, Kanwal F, Richardson P, et al. Am J Gastroenterol. 2010 Nov 9. [Epub ahead of print]


Syringe exchange programs --- United States, 2008. Centers for Disease Control and Prevention (CDC). MMWR Morb Mortal Wkly Rep. 2010 Nov 19;59(45):1488-91.


Evaluation of acute hepatitis C infection surveillance --- United States, 2008. MMWR Morb Mortal Wkly Rep. 2010 Nov 5;59(43):1407-10. Centers for Disease Control and Prevention (CDC).


Fatigue and depressive symptoms associated with chronic viral hepatitis patients. health-related quality of life (HRQOL). Karaivazoglou K, Iconomou G, Triantos C, et al. Ann Hepatol. 2010 Oct 1;9(4):419-27.


Transfusion-transmissible viral infections among US military recipients of whole blood and platelets during Operation Enduring Freedom and Operation Iraqi Freedom. Hakre S, Peel SA, O'Connell RJ, et al. Transfusion. 2010 Oct 7. doi: 10.1111/j.1537-2995.2010.02906.x. [Epub ahead of print]


Patients' perceptions of information and support received from the nurse specialist during HCV treatment. Grogan A, Timmins F. J Clin Nurs. 2010 Oct;19(19-20):2869-78. doi: 10.1111/j.1365-2702.2010.03239.x.


Guidance for clinical trials for children and adolescents with chronic hepatitis C. Wirth S, Kelly D, Sokal E, et al. J Pediatr Gastroenterol Nutr. 2010 Nov 10. [Epub ahead of print]


Liver Cancer


Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH. Salomao M, Yu WM, Brown RS Jr, Emond JC, Lefkowitch JH. Am J Surg Pathol. 2010 Nov;34(11):1630-6.


Synergistic Effect of Celecoxib on 5-fluorouracil-induced Apoptosis in Hepatocellular Carcinoma Patients. Bassiouny AR, Zaky A, Neenaa HM. Ann Hepatol. 2010 Oct 1;9(4):410-8.


Impact of viral load of hepatitis C on the incidence of hepatocellular carcinoma: A population-based cohort study (JPHC Study). Ishiguro S, Inoue M, Tanaka Y, et al.  Cancer Lett. 2010 Oct 28. [Epub ahead of print]


Increased risk for malignant neoplasms among patients with cirrhosis. Kalaitzakis E, Gunnarsdottir SA, Josefsson A, Björnsson E. Clin Gastroenterol Hepatol. 2010 Oct 25. [Epub ahead of print]


Prognostic significance of circumferential cell surface immunoreactivity of glypican-3 in hepatocellular carcinoma. Yorita K, Takahashi N, Takai H, et al. Liver Int. 2010 Oct 21. doi: 10.1111/j.1478-3231.2010.02359.x. [Epub ahead of print]


Factors associated with use of ultrasonography screening for hepatocellular carcinoma among hepatitis B or C carriers. Cho ER, Shin A, Choi KS, Lee HY, Kim J. Cancer Epidemiol. 2010 Oct 12. [Epub ahead of print]


Resveratrol arrests cell cycle and induces apoptosis in human hepatocellular Carcinoma Huh-7 cells. Liao PC, Ng LT, Lin LT, Richardson CD, Wang GH, Lin CC. J Med Food. 2010 Oct 14. [Epub ahead of print]


Comparative Analysis of outcome in patients with hepatocellular carcinoma exceeding the Milan criteria treated with liver transplantation versus partial hepatectomy. Canter RJ, Patel SA, Kennedy T, et al. Am J Clin Oncol. 2010 Oct 8. [Epub ahead of print]


Clinical Presentation of Hepatocellular Carcinoma (HCC) in Asian-Americans Versus Non-Asian-Americans. Wong PY, Xia V, Imagawa DK, Hoefs J, Hu KQ. J Immigr Minor Health. 2010 Oct 2. [Epub ahead of print]


Meta-analysis: interferon improves outcomes following ablation or resection of hepato-cellular carcinoma. Singal AK, Freeman DH Jr, Anand BS. Aliment Pharmacol Ther. 2010 Oct;32(7):851-8. doi: 10.1111/j.1365-2036.2010.04414.x.



Prolonged recurrence-free survival following OK432-stimulated dendritic cell transfer into hepatocellular carcinoma during transarterial embolization. Nakamoto Y, Mizukoshi E, Kitahara M, et al. Clin Exp Immunol. 2010 Nov 19. doi: 10.1111/j.1365-2249.2010.04246.x. [Epub ahead of print]


Effects of interferon treatment on development and progression of hepatocellular carcinoma in patients with chronic virus infection: A meta-analysis of randomized controlled trials. Zhang CH, Xu GL, Jia WD, Li JS, Ma JL, Ge YS. Int J Cancer. 2010 Nov 12. [Epub ahead of print]


Does antiviral therapy for hepatitis B and C prevent hepatocellular carcinoma? Lok AS. J Gastroenterol Hepatol. 2010 Nov 11. doi: 10.1111/j.1440-1746.2010.06576.x. [Epub ahead of print]